Rockefeller Capital Management
AVXL icon

Rockefeller Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Rockefeller Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.2K Sell
13,212
-4,882
-27% -$14.4K ﹤0.01% 3530
2026
Q1 		$55.5K Buy
18,094
+10,542
+140% +$45.7K ﹤0.01% 3222
2025
Q4 		$26.9K Buy
7,552
+152
+2% +$931 ﹤0.01% 3369
2025
Q3 		$65.9K Buy
+7,400
New +$75.1K ﹤0.01% 2774
2023
Q1 		– Sell
-2,700
Closed -$25K – 2120
2022
Q4 		$25K Hold
2,700
– – ﹤0.01% 2708
2022
Q3 		$27K Hold
2,700
– – ﹤0.01% 2636
2022
Q2 		$27K Hold
2,700
– – ﹤0.01% 2566
2022
Q1 		$33K Buy
2,700
+1,500
+125% +$18.4K ﹤0.01% 2494
2021
Q4 		$20K Hold
1,200
– – ﹤0.01% 2638
2021
Q3 		$21K Buy
1,200
+400
+50% +$7.96K ﹤0.01% 2555
2021
Q2 		$18K Buy
800
+300
+60% +$4.44K ﹤0.01% 2518
2021
Q1 		$7K Buy
+500
New +$5.46K ﹤0.01% 2729

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rockefeller Capital Management's AVXL Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Anavex Life Sciences (AVXL) stake by 27% in Q2 2026, selling an estimated $14.4K and leaving 13,212 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3530.

Rockefeller Capital Management first reported a position in AVXL in Q1 2021 and has held it in 12 quarters since. The position peaked at $65.9K in Q3 2025. 180 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Rockefeller Capital Management held 13,212 shares of Anavex Life Sciences worth $34.2K as of Q2 2026.
  • Rockefeller Capital Management sold 4,882 Anavex Life Sciences shares in Q2 2026, an estimated $14.4K.
  • Anavex Life Sciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3530 holding.
  • Rockefeller Capital Management first reported a position in Anavex Life Sciences in Q1 2021 and has held it in 12 quarters since.
  • Rockefeller Capital Management's Anavex Life Sciences position peaked at $65.9K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.